Skip to main content
. 2020 Nov 17;4:PO.20.00263. doi: 10.1200/PO.20.00263

FIG 3.

FIG 3.

Genomic characteristics of advanced gastric cancer (GC) with epidermal growth factor receptor (EGFR) amplification in circulating tumor DNA (ctDNA). (A) Plasma copy number (pCN) versus ctDNA fraction as the maximum observed variant allelic frequency. (B) Frequency of EGFR-amplified GC in ctDNA versus GI-SCREEN and The Cancer Genome Atlas database. For the ctDNA population, the frequency of all EGFR amplifications and high EGFR pCN in GC is shown, respectively. (C) Distribution of the number of ctDNA EGFR mutations in patients with metastatic colorectal cancer after anti-EGFR therapy. (D) Distribution of the number of ctDNA actionable EGFR mutations in patients with metastatic colorectal cancer after anti-EGFR therapy. (****) P < .0001. NS, not significant; TCGA, The Cancer Genome Atlas.